Using an artificial protein that stimulates the body's natural immune system to fight cancer, a research team at Duke Medicine has engineered a lethal weapon that kills brain tumors in mice while sparing other tissue. If it can be shown to work in humans, it would overcome a major obstacle that has hampered the effectiveness of immune-based therapies.
The protein is manufactured with two arms – one that exclusively binds to tumor cells and another that snags the body's fighter T-cells, spurring an attack on the tumor. In six out of eight mice with brain tumors, the treatment resulted in cures, according to findings published Dec. 17, 2012, in the Proceedings of the National Academy of Sciences.
"This work represents a revival of a somewhat old concept that targeting cancer with tumor-specific antigens may well be the most effective way to treat cancer without toxicity," said senior author John H. Sampson, M.D., PhD, a neurosurgeon at The Preston Robert Tisch Brain Tumor Center at Duke. "But there have been problems with that approach, especially for brain tumors. Our therapeutic agent is exciting, because it acts like Velcro to bind T-cells to tumor cells and induces them to kill without any negative effects on surrounding normal tissues."
Sampson and colleagues focused on the immune approach in brain tumors, which are notoriously difficult to treat. Despite surgery, radiation and chemotherapy, glioblastomas are universally fatal, with a median survival of 15 months.
Immunotherapies, in which the body's B-cells and T-cells are triggered to attack tumors, have shown promise in treating brain and other cancers, but have been problematic in clinical use. Treatments have been difficult to administer at therapeutic doses, or have spurred side effects in which the immune system also attacks healthy tissue and organs.
Working to overcome those pitfalls, the Duke-led researchers designed a kind of connector - an artificial protein called a bispecific T-cell engager, or BiTE – that tethers the tumor to its killer. Their newly engineered protein includes fractions of two separate antibodies, one that recruits and engages the body's fighter T-cells and one that expressly homes in on an antigen known as EGFRvIII, which only occurs in cancers.
Once connected via the new bispecific antibody, the T-cells recognize the tumor as an invader, and mount an attack. Normal tissue, which does not carry the tumor antigen, is left unscathed.
"One of the major advantages is that this therapy can be given intravenously, crossing the blood-brain barrier," said lead author Bryan Choi, a dual M.D-PhD candidate at Duke. "When we gave the therapy systemically to the mice, it successfully localized to the tumors, treating even bulky and invasive tumors in the central nervous system."
The team also developed an antidote to other current immune-targeting therapies that have a toxic effect, enhancing their safety profiles and bolstering their effectiveness.
"Additional studies will concentrate on whether these findings can be replicated in human trials, and whether the treatment is affected by the use of current therapies such as radiation and chemotherapy," Sampson said.
Duke University Medical Center: http://www.dukemednews.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Fans of "Flappy Bird" may find its successor even more frustrating, but just as addictive
Even just the word Ebola is kind of terrifying. Why? Hollywood has a lot to do with it. But Ebola outbreaks also have all the ingredients for what one psychologist calls the "dread factor."
If we want to understand whats happening in the brain when people hear voices, we first need to understand what happens during ordinary inner speechHearing voices: whats your experience when reading?
Seals and sea lions may have brought a form of tuberculosis to the Americas, centuries before the Spanish did so
More people with non-fatal conditions are travelling to assisted dying clinics in Switzerland
We’re all born to adore ourselves, but not all of us grow up
Rumours of dubious treatments are spreading on social media in West Africa, while fishy Ebola treatments are being peddled to anxious US citizens
The type of Ebola erupting in West Africa is closely related to one found 2,500 miles away — the distance between Boston and San Francisco. How did the virus spread so far without anyone noticing?
The tendency of Clostridium novyi to kill mammal cells has been used to shrink tumours in dogs and people, so the bacteria could help fight some cancers
The Burns Collection consists of human cadavers from the early 1800s that were anatomically dissected and preserved to teach anatomy and surgery to medical students. For the first time this portion of the collection is on display to the public as a part of traveling exhibit "Mummies of the World: The Exhibition."